ANIP News and Press, ANI Pharmaceuticals Inc. From 04/24/23

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml. ANI’s Nitrofurantoin Oral Suspension is th...

2023-04-04 07:29:16 ET The U.S. Food and Drug Administration (FDA) approved ANI Pharmaceuticals' ( NASDAQ: ANIP ) generic cholesterol-lowering drug, Colestipol Hydrochloride Tablets USP 1 g. The company said its Colestipol Hydrochloride tablets are the generic version of the r...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g. ANI’s Colestipol Hydrochloride Tablets are the ...

2023-03-10 17:31:23 ET Amid concerns about smaller pharma and biotech companies' exposure to Silicon Valley Bank ( SIVB ), a number of them have disclosed that they have no relationship with the FDIC-shuttered financial institution . Among the larger ones are Cara Therapeu...

2023-03-09 13:10:20 ET ANI Pharmaceuticals, Inc. (ANIP) Q4 2022 Earnings Conference Call March 09, 2023, 08:30 ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President, CEO & Director Stephen Carey - CFO, SVP, Finance & Corporate Secretary ...

2023-03-09 06:52:38 ET ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q4 Non-GAAP EPS of $0.76 beats by $0.09 . Revenue of $94.2M (+54.7% Y/Y) beats by $8.06M . Cash and cash equivalents were $48.2 million, net accounts receivable was $165.4 million, and f...

Fourth Quarter and Full Year 2022 Financial Results -- Q4 net revenues of $94.2 million, net loss available to common shareholders of $(4.7) million and diluted GAAP loss per share of $(0.28) – -- Q4 Adjusted non-GAAP EBITDA of $23.3 million and adjusted non-GAAP diluted ...

2023-03-08 13:03:50 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q4 earnings results on Thursday, March 9th, before market open. The consensus EPS Estimate is $0.67 (+24.1% Y/Y) and the consensus Revenue Estimate is $86.14M (+41.4% Y/Y). Over the la...

2023-03-08 10:27:33 ET Major earning expected before the bell on Thursday include: Arrival ( ARVL ) FuelCell Energy ( FCEL ) JD.com ( JD ) Paysafe ( PSFE ) Village Farms International ( VFF ) For further details see: Notable earnings befor...

ANI Pharmaceuticals ( NASDAQ: ANIP ) gained ~3% in the morning hours Wednesday, marking the biggest intraday gain since late January, after Guggenheim launched its coverage with a Buy recommendation citing the company’s hormonal autoimmune therapy Cortrophin Gel. Cortrophin...